发明名称 |
Effective vector platform for gene transfer and gene therapy |
摘要 |
The invention relates to the discovery that mutations of serine residues of an AAV capsid results in significantly greater transfection efficiency than the wild type AAV2 virus. In one embodiment, the present invention provides a method of improving efficiency of gene transfer and/or gene therapy to a cell by inhibiting phosphorylation of one or more serine residues of a virus capsid protein, where the inhibition of the phosphorylation of one or more serine residues results in a decrease of ubiquitination of the virus capsid protein in the cell. In another embodiment, one of the one or more serine residues is Serine 264. In another embodiment, the Serine 264 residue is mutated to Alanine (S 264 A). |
申请公布号 |
US9133479(B2) |
申请公布日期 |
2015.09.15 |
申请号 |
US201013375285 |
申请日期 |
2010.06.03 |
申请人 |
Cedars-Sinai Medical Center |
发明人 |
Sharifi Behrooz;Shah Prediman K. |
分类号 |
C12N15/86;C07K14/005 |
主分类号 |
C12N15/86 |
代理机构 |
Nixon Peabody LLP |
代理人 |
Levy Seth D.;Nixon Peabody LLP |
主权项 |
1. A vector, comprising:
an isolated adeno-associated virus (AAV) capsid comprising SEQ. ID. NO.: 2 or SEQ ID NO: 3 that resist ubiquitination. |
地址 |
Los Angeles CA US |